致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年10月31日 狀態: 新提交 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2023年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 03759 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | | 增加 / 減少 (-) | | | 0 | | | RMB | | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301 ...

Stock code: 300759.SZ Stock code: 3759.HK 2 0 2 3 ...

证券代码：300759 证券简称：康龙化成 康龙化成（北京）新药技术股份有限公司投资者关系活动记录表 编号：2023-07 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 □新闻发布会 □路演活动 活动类别 □现场参观 √其他 （电话会议） 高盛证券、浙商证券、中金证券、长江证券、招商证券、国盛证券、野 村证券、招商国际、华泰证券、国泰君安证券、中信建投、广发证券、 平安证券、中信证券、国金证券、兴业证券、浙商证券、天风证券、交 参与单位名称及 银施罗德基金、嘉实基金、汇丰晋信基金、贝莱德、国投瑞银、银华基 人员姓名 金、银河基金、泰康资产（香港）、华安基金、光大保德信基金、高毅 资产、广发基金、人保资产、摩根华鑫、等 200 余家机构 300 余名参与 人员 时 间 2023年 10月30日09:00-11:30 地 点 公司会议室 上市公司接待人 首席财务官、董事会秘书：李承宗先生 员姓名 第一部分：公司管理层对 2023年第三季度报告进行分析解读。 1、 2023年前三季度整体业绩 ...

Financial Performance - The company's adjusted net profit attributable to shareholders for 1-3Q2023 was RMB 1,412 million, up from RMB 1,328 million in 1-3Q2022, reflecting a growth of 6.3% [39] - The adjusted net profit growth rate, excluding the impact of biological assets, was significant [10] Revenue Breakdown - Revenue from domestic delivery increased by 14.1%, accounting for 87% of total revenue [14] - Revenue from overseas delivery grew by 26.7%, making up 13% of total revenue [14] - Revenue from the top 20 pharmaceutical companies increased by 5.4%, while revenue from other existing clients rose by 19.0% [14] - New clients contributed 6.2% to total revenue [14] Business Segments - The mature business segment, excluding large molecules and CGT services, showed a steady growth in adjusted net profit [19] - The company has been expanding its large molecule and CGT services since 2021 through self-built and acquisition strategies, currently in the investment phase [19] - The company acquired CMC (small molecule CDMO) service capacities in the UK and the US in 2022, which are in the early stages of integration [19] Compliance and Confidentiality - The document is confidential and not subject to any regulatory review, and its distribution may be legally restricted in certain jurisdictions [3] - The information provided does not constitute an investment decision basis and is not an offer or invitation to purchase any securities [3][4]

Financial Performance - The company's revenue for Q3 2023 reached ¥2,920,138,789.43, representing a year-on-year increase of 5.49%[4] - The net profit attributable to shareholders for Q3 2023 was ¥352,944,967.45, a decrease of 6.05% compared to the same period last year[4] - The adjusted net profit attributable to shareholders under non-IFRS was ¥480,583,101.41, down 6.82% year-on-year[4] - Total revenue for the period reached ¥8,560,256,911.27, an increase of 15.6% compared to ¥7,402,793,998.96 in the previous period[26] - The net profit for Q3 2023 was CNY 1,134,523,142.41, an increase of 20.2% compared to CNY 944,178,254.54 in Q3 2022[27] - The company reported a total comprehensive income of CNY 1,107,456,956.68 for Q3 2023, compared to CNY 899,030,529.31 in Q3 2022, marking a growth of 23.2%[28] - Basic earnings per share for Q3 2023 were CNY 0.6430, up from CNY 0.5412 in the same period last year, representing an increase of 18.8%[28] Revenue Sources - Revenue from the top 20 global pharmaceutical companies amounted to approximately ¥124,923.91 million, a year-on-year increase of 5.44%[10] - Revenue from overseas laboratories and factories grew by 26.70% year-on-year, accounting for 13.34% of total revenue[9] - Revenue from clinical research services reached ¥1,262,099,160.97, marking a year-on-year increase of 28.48%[8] Cash Flow and Assets - The company reported a net cash flow from operating activities of ¥2,029,402,975.72, reflecting a significant increase of 45.47% year-to-date[4] - Cash and cash equivalents rose by 37.48% to ¥2,058,719,211.34, with an increase of ¥56,123.54 million from the previous year[13] - The total assets at the end of Q3 2023 were ¥22,476,012,563.70, an increase of 9.68% from the end of the previous year[4] - The cash flow from operating activities generated a net amount of CNY 2,029,402,975.72, compared to CNY 1,395,070,031.14 in the previous year, indicating a significant increase of 45.4%[29] - The cash and cash equivalents at the end of Q3 2023 amounted to CNY 2,022,842,617.58, an increase from CNY 1,691,911,763.98 at the end of Q3 2022[30] Expenses and Liabilities - Total operating costs amounted to ¥7,354,768,450.44, up from ¥6,289,455,335.33, reflecting a year-over-year increase of 16.9%[26] - The total liabilities increased to ¥9,749,326,551.15 from ¥9,652,689,512.90, reflecting a rise of 1.0%[25] - The company's total operating expenses increased to CNY 10,928,665.52, down from CNY 17,687,425.20 in Q3 2022, indicating improved cost management[27] Research and Development - R&D expenses increased by 67.22% to ¥296,764,121.85, reflecting the company's commitment to enhancing R&D capabilities and technical expertise[14] - Research and development expenses increased significantly to ¥296,764,121.85, compared to ¥177,468,493.98, marking a growth of 67.1%[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 66,106[16] - The top 10 shareholders hold a total of 1,020,000,000 shares, representing approximately 61.54% of total shares[16] - HKSCC NOMINEES LIMITED holds 16.87% of shares, amounting to 301,502,038 shares[16] - Shenzhen Xinchengkang Investment Partnership holds 14.63% of shares, totaling 261,427,958 shares[16] - Pharmaron Holdings Limited owns 10.10% of shares, equating to 180,496,500 shares[16] Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance growth[26] - The company continues to expand its integrated pharmaceutical R&D services globally, maintaining a focus on customer-centric strategies[9]

Financial Performance - Q3 2023 revenue reached ¥2,920,138,789.43, an increase of 5.49% year-over-year, while year-to-date revenue totaled ¥8,560,256,911.27, up 15.64% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was ¥352,944,967.45, a decrease of 6.05% year-over-year, with year-to-date net profit at ¥1,139,038,016.10, an increase of 18.51%[4] - Total revenue for the nine months ended September 30, 2023, was RMB 8,560,257,000, an increase from RMB 7,402,794,000 in the same period of 2022, representing a growth of approximately 15.6%[45] - Net profit attributable to the owners of the parent company for the period was RMB 1,139,038,000, up from RMB 961,107,000 in the previous year, marking an increase of about 18.5%[45] - Basic earnings per share for the period was RMB 0.6430, compared to RMB 0.5412 in the same period of 2022, showing an improvement of approximately 18.8%[45] Revenue Breakdown - Revenue from laboratory services for the first three quarters of 2023 was ¥5,069,130,773.99, a year-over-year increase of 13.65%[5] - Revenue from CMC (small molecule CDMO) services was ¥1,913,656,858.43, with a year-over-year increase of 13.94%[5] - Revenue from clinical research services reached ¥1,262,099,160.97, reflecting a year-over-year growth of 28.48%[5] - Revenue from the top 20 global pharmaceutical companies was approximately ¥124,923.91 million, a year-over-year increase of 5.44%, accounting for 14.59% of total revenue[6] - Revenue from overseas laboratories and factories grew by 26.70%, representing 13.34% of total revenue[6] Profitability Metrics - The gross profit margin for laboratory services was 44.38% in the first three quarters of 2023, compared to 45.02% in the same period last year[5] - The company's main business gross margin for the first three quarters of 2023 was 35.97%, slightly down from 36.49% in the previous year[6] - Gross profit for the same period was RMB 3,059,800,000, compared to RMB 2,687,250,000 in 2022, indicating a gross margin improvement[45] Cash Flow and Assets - Cash flow from operating activities for the year-to-date period was ¥2,029,402,975.72, an increase of 45.47% compared to the previous year[4] - The net cash flow from operating activities increased by 45.47% to CNY 2,029,402,975.72 compared to the same period last year[10] - Cash inflow from investment activities totaled ¥2,107,544,066.88, down from ¥3,924,361,583.36 in the previous period[42] - As of September 30, 2023, total assets reached CNY 22.48 billion, an increase from CNY 20.49 billion at the beginning of the year, reflecting a growth of approximately 9.7%[21] - Current assets amounted to CNY 7.22 billion, up from CNY 6.54 billion, indicating a growth of about 10.4%[22] Liabilities and Equity - Total liabilities were reported at CNY 9.75 billion, slightly increasing from CNY 9.65 billion, representing a growth of approximately 0.9%[25] - The company's equity attributable to shareholders rose to CNY 11.90 billion from CNY 10.55 billion, marking an increase of around 12.8%[26] - Non-current liabilities increased to RMB 6,036,403,000 from RMB 5,740,256,000 at the beginning of the year, reflecting a rise of approximately 5.2%[48] Research and Development - R&D expenses rose by 67.22% to CNY 296,764,121.85, reflecting the company's commitment to enhancing R&D capabilities[12] - Research and development expenses increased to ¥296,764,121.85, a rise of 67.1% from ¥177,468,493.98 in the previous period[30] Shareholder Information - The total number of common shareholders at the end of the reporting period was 66,106, with no preferred shareholders[14] - The top ten shareholders hold a combined 53.11% of the shares, with HKSCC NOMINEES LIMITED holding the largest share at 16.87%[15] - The total number of restricted shares at the beginning of the period was 48,169,260, with 21,420,000 shares added during the period, resulting in a total of 64,260,000 restricted shares at the end[18] Other Financial Metrics - The company reported a basic earnings per share of 0.6430, compared to 0.5412 in the previous period, reflecting a growth of 18.8%[37] - The company incurred a financial expense of ¥108,844,237.57, down from ¥161,865,447.67 in the previous period, showing a decrease of 32.7%[30] - The total amount of non-operating income and expenses was CNY 24,393,822.75 for the current period[7] - The company reported a profit before tax of RMB 1,320,946,000 for the nine months ended September 30, 2023, compared to RMB 1,207,470,000 in the same period of 2022, reflecting a year-over-year increase of approximately 9.4%[45]

签名： 独立董事：周其林 签名： 独立董事：李丽华 签名： 独立董事：曾坤鸿 签名： 独立董事：余坚 此次预计的日常关联交易事项有助于扩大公司经济效益，双方是按照客观公 平、平等自愿、互惠互利的市场原则，以公允的价格和交易条件及签署书面合同 的方式，确定双方的权利义务关系，符合商业惯例。该项交易不存在损害公司及 股东，特别是中小股东利益的情形，我们同意将此议案提交公司第三届董事会第 四次会议审议，关联董事需回避表决。 （以下无正文） [本页无正文，为《康龙化成（北京）新药技术股份有限公司独立董事关于第三 届董事会第四次会议有关事项的事前认可意见》的签署页] 康龙化成（北京）新药技术股份有限公司独立董事 关于第三届董事会第四次会议有关事项的事前认可意见 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》《上市公司独立董事管理办 法》等相关法律、法规及规范性文件，以及康龙化成（北京）新药技术股份有限 公司（以下简称"公司"）《公司章程》和《独立非执行董事工作制度》等有关 规定，我们作为公司独立董事，就公司第三届董事会第四次会议审议的有关事项 发表事 ...

证券代码：300759 证券简称：康龙化成 公告编号：2023-098 一、2021年A股激励计划已履行的决策程序和批准情况 （一）2021年6月9日，公司分别召开第二届董事会第十二次会议、第二届监 事会第八次会议，审议通过了《关于<康龙化成（北京）新药技术股份有限公司 2021年A股限制性股票激励计划（草案）>及其摘要的议案》《关于<康龙化成（北 京）新药技术股份有限公司2021年A股限制性股票激励计划实施考核管理办法> 的议案》《关于提请股东大会授权董事会办理A股股权激励相关事宜的议案》， 公司独立董事对相关议案发表了同意的独立意见。 （二）2021年6月10日至2021年6月20日，公司通过公司内部OA系统公示了 《2021年A股限制性股票激励计划激励对象名单》。在公示的期限内，公司监事 会未收到任何针对本次拟激励对象的异议。2021年7月7日，公司公告了《监事会 关于2021年A股限制性股票激励计划激励对象名单的核查意见及公示情况说明》， 1 康龙化成（北京）新药技术股份有限公司 关于调整 2021 年、2022 年 A 股限制性股票激励计划 相关事项的公告 本公司及董事会全体成员保证信息披露的内容真 ...

上海信公轶禾企业管理咨询有限公司 关于 康龙化成（北京)新药技术股份有限公司 2021 年 A 股限制性股票激励计划 第二个归属期归属条件成就相关事项 之 独立财务顾问报告 独立财务顾问： 二〇二三年十月 上海信公轶禾企业管理咨询有限公司 独立财务顾问报告 目 录 | 第一章 | 声 明 3 | | --- | --- | | 第二章 | 释 义 5 | | 第三章 | 基本假设 7 | | 第四章 | 本激励计划履行的审批程序 8 | | 第五章 | 本激励计划第二个归属期归属条件成就情况 10 | | | 一、董事会就本次激励计划设定的限制性股票归属条件是否成就的审议情况 10 | | | 二、第二个归属期情况 10 | | | 三、第二个归属期归属条件成就的说明 10 | | | 四、本次实施的激励计划与已披露的激励计划相关情况的差异 11 | | 第六章 | 本次限制性股票可归属的具体情况 13 | | | 一、本次可归属的激励对象及归属数量 13 | | | 二、本次归属条件成就之日和第二个归属期限制性股票继续禁售的说明 13 | | 第七章 | 独立财务顾问的核查意见 15 | 2 上海信公轶禾企 ...

北京市中伦律师事务所 关于康龙化成（北京）新药技术股份有限公司 2022 年 A 股限制性股票激励计划授予价格及数量调 整、第一个归属期归属条件成就但股票暂不上市 及部分限制性股票作废事项的 法律意见书 二〇二三年十月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty | 一、本次调整、本次归属及本次作废的批准与授权 3 | | --- | | 二、本次调整的具体内容 4 | | 三、本次归属的具体情况 5 | | 四、本次作废的具体情况 7 | | 五、结论意见 7 | 北京市朝阳区金和东路 20 号 ...